Amid concerns over new UK COVID-19 strain, vaccine maker submits data for emergency use
Apart from SII and Bharat Biotech, Pfizer has applied for the EUA so far but the US based pharma major has sought more time to make a detailed presentation before the Covid subject expert committee.
Share Via Email
| A+A A- By Express News Service
NEW DELHI: One of the two Indian vaccine makers Serum Institute of India and Bharat Biotech has presented additional data demanded by the apex drug regulator in response to their application for emergency use authorization of Covid vaccine.
Apart from SII and Bharat Biotech, Pfizer has applied for the EUA so far but the US based pharma major has sought more time to make a detailed presentation before the Covid subject expert committee of the Central Drugs Standards Control Organisation.
India may need 1.3 lakh-1.4 lakh Covid vaccination centres: Study
Premium
(AP)
Share Via
Read Full Story
New Delhi: For Covid-19 vaccination, India may need 1.3 lakh-1.4 lakh vaccination centres, 1 lakh healthcare professionals as inoculators and 2 lakh support staff or volunteers to support government’s mass-inoculation program, a FICCI-EY knowledge paper has indicated.
The paper on private healthcare players to augment government’s capacity across the value chain of vaccine distribution and administration also highlighted that 81% of survey respondents from private healthcare industry are willing to inoculate frontline workers in local areas and 75% are willing to inoculate their local communities,70% are willing to allocate manpower in semi-urban/rural areas for vaccination and 94% are willing to impart training for inoculation.
How India plans to ensure safety and efficacy of covid-19 vaccines
The meeting of the subject expert committee of Central Drugs Standards Control Organisation has asked Bharat Biotech International and Serum Institute of India for more data on the safety and efficacy of their shots.Premium
3 min read
Share Via
Read Full Story
NEW DELHI: Safety and efficacy are the primary concerns of the government while granting emergency use authorization (EUA) to any covid-19 vaccine in the country.
The government s cautious approach before approving a vaccine is apparent. The meeting of the subject expert committee of Central Drugs Standards Control Organisation on Wednesday asked Bharat Biotech International and Serum Institute of India for more data on the safety and efficacy of their shots and deferred recommending them for emergency use.
So far, the Indian regulator has not granted regulatory approvals to any vaccine candidate based on data generated during trials held in other countries. | Health
The health minister was digitally addressing the Inter-Ministerial meeting on Vaccination of South Asia against covid-19 by the World Bank on Thursday.Pune-based SII is in a process to manufacture Covishield which undergoing phase 3 stage of the clinical trials